期刊文献+

Assessment of the efficacy and safety of bronchial artery perfusion chemotherapy combined with high-frequency hyperthermia for advanced non-small cell lung cancer

下载PDF
导出
摘要 Objective:To study the efficacy and safety of bronchial artery perfusion chemotherapy combined with high-frequency hyperthermia for advanced non-small cell lung cancer. Methods:Patients with advanced non-small cell lung cancer who were treated in Navy General Hospital between May 2014 and October 2016 were selected and randomly divided into two groups, the observation group received bronchial arterial infusion chemotherapy combined with high-frequency hyperthermia, and the control group received bronchial arterial infusion chemotherapy. Before and after treatment, the expression of tumor activity indexes and liver and kidney function indexes in serum as well as and proliferation and invasion genes in tumor lesions were detected respectively.Results: 5 d and 7 d after treatment, serum CEA, MIF, CYFRA21-1 and HE4 levels of both groups of patients were significantly lower than those before treatment and serum CEA, MIF, CYFRA21-1 and HE4 levels of observation group were significantly lower than those of control group;7 d after treatment, MEF2D, c-myc, Survivin, Bcl-2, Vimentin, N-cadherin and Slug expression in tumor lesions of both groups of patients were significantly lower than those before treatment and MEF2D, c-myc, Survivin, Bcl-2, Vimentin, N-cadherin and Slug expression in tumor lesions of observation group were significantly lower than those of control group;serum Scr, BUN, ALT and AST levels were not significantly different between two groups of patients before and after treatment. Conclusion:Bronchial artery perfusion chemotherapy combined with high-frequency hyperthermia for advanced non-small cell lung cancer can significantly inhibit the tumor proliferation and invasion and is with ideal safety.
出处 《Journal of Hainan Medical University》 2017年第11期132-136,共5页 海南医学院学报(英文版)
基金 Natural Science Foundation of China(30670612) China International Medical Foundation(Z-2014-06-15322) Navy Logistics Department(HJHQ-20130987).
  • 相关文献

参考文献3

二级参考文献24

  • 1E1-Badrawy MK, Yousef AM, Shaalan D,et al. Matrix metallo- proteinase-9 expression in lung cancer patients and its relation to serum mmp 9 activity, pathologic type, and prognosis[J]. J Bronchology Interv Pulmonol, 2014,21 (4) : 327-334.
  • 2Braicu EI, Chekerov R, Richter R, et al. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse[J3. Ann Surg Oncol, 2014,21(3) :955-962.
  • 3Iwahori K, Suzuki H, Kishi Y, et al. Serum HE4 as a diagnos tic and prognostic marker for lung caneer[J]. Tumour Biol, 2012,33(4) : 1141-1149.
  • 4Liang Y, Ma T, Thakur A,et al. Differentially expressed glyco- sylated patterns of alpha-l-antitrypsin as serum biomarkers for the diagnosis of lung caneer[J]. Glycobiology, 2015,25 (3) 331- 40.
  • 5Angioli R,Miranda A,Aloisi A, et al. A critical review on HE4 performance in endometrial cancer: where are we now [J]. Tumour Biol,2014,35(2) :881 887.
  • 6Liu W, Yang J, Chi PD, et al. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis [J]. Int J Tuberc Lung Dis,2013,17(10) :1346 1353.
  • 7Nagy B Jr, Bhattoa HP, Steiber Z, et al. Serum human epididy- mis protein 4 (HE4) as a tumor marker in men with lung canc- er[J]. ClinChem LabMed,2014,52(ll):1639-1648.
  • 8Wang X, Fan Y,Wang J, et al. Evaluating the expression and di agnostic value of human epididymis protein 4 (HE4) in small cell lung cancer[J]. Tumour Biol,2014 ,35(7)6847 6853.
  • 9Yang J,Sa M, Huang M, et al. The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemilumines- cenee immunoassay[J]. Clin Biochem, 2013,46 ( 16-17 ) .- 1705- 1708.
  • 10上官红,肖伟,董亮,李玉,田辉,郑天郢.血清CYFRA21-1、NSE和CEA在肺癌诊断和评估预后中的临床价值[J].山东大学学报(医学版),2010,48(12):134-137. 被引量:13

共引文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部